We generate and disseminate cutting-edge, applied knowledge on explicit priority setting in health and drug prices intervention strategies in order to promote evidence-based decision making on what to finance in health with public resources and how much pay for it. In this section you will find valuable information on Health Technology Assessment (HTA), Health Benefit Plans (HBP), pharmaceutical policy, drugs and medical devices regulation, catastrophic funds, and horizon scanning, among others.
WEBINARS
Is it possible to use unbranded generics to improve people's access to health care and reduce household out-of-pocket spending?
Join us for a webinar where we will present the results of studies conducted by the IDB's Criteria Network in Chile and the Dominican Republic on the potential savings that could be achieved by switching to generic drugs.
Is it possible to use unbranded generics to improve people's access to health care and reduce household out-of-pocket spending?
Join us for a webinar where we will present the results of studies conducted by the IDB's Criteria Network in Chile and the Dominican Republic on the potential savings that could be achieved by switching to generic drugs.
The hidden costs of financing high-cost medicines: the cases of Colombia and the Dominican Republic.
In this webinar, we will discuss the impact of financing high-cost medicines from a population health perspective.
Join us to learn about the cases of Colombia and the Dominican Republic, the budgetary impact of purchasing these types of medicines, their opportunity costs and some tools to achieve more efficient health spending.
GO TO ALL WEBINARSMOOC
PUBLICATIONS CRITERIA
Breves
Breves
Breves
Breves
Breves
Breves
Breves
Breves
Breves
Breves
